Sale

Warm Autoimmune Hemolytic Anemia Market

Warm Autoimmune Hemolytic Anemia Market Size, Share, Growth: By Drug Class: Fostamatinib, Sutimlimab, Parsaclisib, Rilzabrutinib, Isatuximab; By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies; Regional Analysis; Market Dynamics: Market Drivers and Constraints; Supplier Landscape; 2024-2032

Warm Autoimmune Hemolytic Anemia Market Outlook

The warm autoimmune hemolytic anemia market size is expected to grow at a CAGR of 15.9% during the forecast period of 2024-2032, driven by the heightened awareness surrounding autoimmune diseases along with the growing research initiatives focused on the development of novel therapies across the 8 major markets. 

 

Warm Autoimmune Hemolytic Anemia Market Overview

Warm autoimmune hemolytic anemia (wAIHA) is considered the most common type of autoimmune hemolytic anemia, affecting about 1 to 3 adults in every 100,000 individuals . The autoimmune disorder is caused by autoantibodies that react with self-red blood cells (RBCs) and destroy them, resulting in anemia. These antibodies are active at body temperature and are present in 80% of the cases. It particularly targets older red blood cells.

 

Autoimmune hemolytic anemia usually occurs among older adults, with the majority of the patients aged 40 or above at the time of diagnosis. The rise in the geriatric population size is expected to drive the warm autoimmune hemolytic anemia market demand, as more and more elderly patients will need effective therapeutics to manage the condition. Moreover, the growing awareness among patients as well as healthcare providers is encouraging treatment-seeking behaviour, improving diagnosis rates, and ultimately propelling market growth.

 

The market is driven by increasing research initiatives to develop and commercialize safer and more effective treatment therapies to manage this autoimmune disorder. In November 2023, a study published in the American Journal of Hematology revealed Phase 3 FORWARD trial results of Fostamatinib (an oral spleen tyrosine kinase inhibitor) for warm autoimmune hemolytic anemia patients. The data suggested clinically significant outcomes for the patients in North America, Australia, and Western Europe, indicating the potential of fostamatinib in inducing durable hemoglobin responses. The increased number of clinical trials will aid in bringing promising treatment solutions to the rising patient population, thereby supporting warm autoimmune hemolytic anemia market growth.

 

The market is witnessing increased collaboration and partnerships among the key market players as well as research institutes. This accelerates development and innovation in the treatment landscape. The market is also driven by favourable regulatory reforms by the health agencies such as the United States Food and Drug Administration (FDA) which helps in addressing the clinical needs of patients suffering from warm autoimmune hemolytic anemia. Moreover, the rising technological innovation in diagnostics and the increased healthcare expenditure will fuel market growth in the coming years.

 

Warm Autoimmune Hemolytic Anemia Market Trends

Key Trend Impact
Advancements in Treatment Options The development of new therapies and treatment options has elevated the market value. Novel treatments which target specific pathways involved in the autoimmune response are exhibiting positive results in clinical trials, offering promising alternatives to traditional corticosteroids and splenectomy, which are associated with certain side effects and risks. These advancements improve efficacy and patient outcomes and drive market growth by addressing the unmet clinical need for safe and effective treatment options.
Technological Innovations in Diagnostics The warm autoimmune hemolytic anemia market share is further propelled by the advent of technological advancements in diagnostic technologies such as next-generation sequencing and advanced immunophenotyping are facilitating quick and accurate identification and classification of the condition. These technologies enable a more precise understanding of the cause of the disease, aiding in personalized treatment approaches. By improving diagnostic accuracy and speed, technological innovations enhance patient care and help in identifying a larger patient population eligible for targeted treatments, thereby driving market demand.
Rising Patient Awareness and Diagnosis Rates One of the significant warm autoimmune hemolytic anemia market trends is the heightened awareness among healthcare providers and the public about autoimmune hemolytic anemias, including warm autoimmune hemolytic anemia, which has led to higher diagnosis rates. Early and accurate diagnosis lays the foundation for effective management of the disease, reducing the risk of severe complications. This trend is driving demand for diagnostic and therapeutic options, attracting investment in research and development, and consequently boosting market growth. 
Favourable Regulatory and Reimbursement Frameworks Changes in regulatory policies and reimbursement frameworks significantly impact the market landscape. Faster regulatory approvals for innovative treatments enhance market access and patient adoption rates. Moreover, favorable reimbursement policies for new and existing therapies ensure that more patients can afford these life-saving treatments, thereby expanding the market size. This regulatory and reimbursement support also encourages pharmaceutical companies to invest in the development of new therapies, ultimately driving growth in the market.

 

Warm Autoimmune Hemolytic Anemia Market Segmentation

Market Breakup by Drug Class
  

  • Fostamatinib
  • Sutimlimab
  • Parsaclisib
  • Rilzabrutinib
  • Isatuximab

 

The market is segmented by drug class into Fostamatinib, Sutimlimab, Parsaclisib, Rilzabrutinib, and Isatuximab. This segment covers various therapeutic options available in the market for managing warm autoimmune hemolytic anemia.

 

Market Breakup by Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

 

In terms of distribution channels, the warm autoimmune hemolytic anemia market share comprises hospital pharmacies, online pharmacies, and retail pharmacies. These channels offer a robust network to facilitate access to medications for patients with this autoimmune disorder according to their needs and convenience.

 

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan
  • India

 

Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and India. The United States leads the market share, owing to the high prevalence of autoimmune diseases in the region including warm autoimmune hemolytic anemia. Further, the presence of an advanced healthcare infrastructure fuels the development of novel therapeutics and diagnostics tools for the treatment of this autoimmune disorder. Other factors that propel the market growth are the increasing investment in the healthcare industry and growing research activities in the regional market.

 

Warm Autoimmune Hemolytic Anemia Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Rigel Pharmaceuticals
  • Apellis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Sanofi
  • Incyte Corporation
  • Momenta Pharmaceuticals
  • Teva Pharmaceuticals Ltd.
  • F. Hoffmann La Roche Ltd.
  • Alexion Pharmaceuticals Inc.
  • Immunovant

 

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class 
  • Distribution Channel
  • Region
Breakup by Drug Class 
  • Fostamatinib
  • Sutimlimab
  • Parsaclisib
  • Rilzabrutinib
  • Isatuximab  
Breakup by Distribution Channel
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies 
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
  • India 
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Rigel Pharmaceuticals 
  • Apellis Pharmaceuticals, Inc. 
  • Johnson & Johnson 
  • Sanofi
  • Incyte Corporation 
  • Momenta Pharmaceuticals 
  • Teva Pharmaceuticals Ltd. 
  • F. Hoffmann La Roche Ltd. 
  • Alexion Pharmaceuticals Inc. 
  • Immunovant 

 

Key Queries Solved in the Warm Autoimmune Hemolytic Anemia Market Report 

  • How has the market performed so far and how will it perform in the coming years?
  • What are the major market trends influencing the market? 
  • What are the market's major drivers, opportunities, and restraints? 
  • What will be the effect of each driver, challenge, and opportunity on the market? 
  • Which regional market is expected to lead the market share in the forecast period? 
  • Which country is expected to experience expedited growth during the forecast period? 
  • How does the prevalence and incidence of warm autoimmune hemolytic anemia affect the market landscape?
  • How do the advancements in treatment options impact the warm autoimmune hemolytic anemia market size?
  • Which drug class will dominate the market share? 
  • Which distribution channel is expected to have a high market value in the coming years?
  • How will the ongoing clinical trials impact market growth during the forecast period? 
  • What are the factors driving regional disparities in warm autoimmune hemolytic anemia treatment and outcomes?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Warm Autoimmune  Hemolytic Anemia Market Overview – 8 Major Markets 

    3.1    Warm Autoimmune Hemolytic Anemia Market Historical Value (2017-2023) 
    3.2    Warm Autoimmune Hemolytic Anemia Market Forecast Value (2024-2032) 
4    Warm Autoimmune Hemolytic Anemia Overview 
    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Treatment Pathway 
5    Patient  Profile
    5.1    Patient Profile Overview
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Treatment Success Rate
6    Warm Autoimmune Hemolytic Anemia Epidemiology Scenario and Forecast – 8 Major Markets
    6.1    8MM Epidemiology Scenario Overview (2017-2032)
    6.2    United States Warm Autoimmune Hemolytic Anemia Epidemiology Scenario and Forecast (2017-2032)
    6.3    EU-4 and United Kingdom Warm Autoimmune Hemolytic Anemia Epidemiology Scenario and Forecast (2017-2032)
        6.3.1    Germany Warm Autoimmune Hemolytic Anemia Epidemiology Scenario and Forecast (2017-2032)
        6.3.2    France Warm Autoimmune Hemolytic Anemia Epidemiology Scenario and Forecast (2017-2032)
        6.3.3    Italy Warm Autoimmune Hemolytic Anemia Epidemiology Scenario and Forecast (2017-2032)
        6.3.4    Spain Warm Autoimmune Hemolytic Anemia Epidemiology Scenario and Forecast (2017-2032)
        6.3.5    United Kingdom Warm Autoimmune Hemolytic Anemia Epidemiology Scenario and Forecast (2017-2032)
    6.4    Japan Warm Autoimmune Hemolytic Anemia Epidemiology Scenario and Forecast (2017-2032) 
    6.5    India Warm Autoimmune Hemolytic Anemia Epidemiology Scenario and Forecast (2017-2032)
7    Warm Autoimmune Hemolytic Anemia Market Landscape – 8 Major Markets 
    7.1    Warm Autoimmune Hemolytic Anemia: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Warm Autoimmune Hemolytic Anemia: Product Landscape
        7.2.1    Analysis by Drug Class
        7.2.2    Analysis by Distribution Channel 
8    Warm Autoimmune Hemolytic Anemia Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Warm Autoimmune Hemolytic Anemia Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Warm Autoimmune Hemolytic Anemia Market Segmentation (2017-2032) - 8 Major Markets 
    11.1    Warm Autoimmune Hemolytic Anemia Market (2017-2032) by Drug Class 
        11.1.1    Market Overview
        11.1.2    Fostamatinib
        11.1.3    Sutimlimab
        11.1.4    Parsaclisib
        11.1.5    Rilzabrutinib
        11.1.6    Isatuximab   
    11.2    Warm Autoimmune Hemolytic Anemia Market (2017-2032) by Distribution Channel
        11.2.1    Market Overview
        11.2.2    Hospital Pharmacies
        11.2.3    Online Pharmacies
        11.2.4    Retail Pharmacies 
    11.3    Warm Autoimmune Hemolytic Anemia Market (2017-2032) by Region
        11.3.1    Market Overview
        11.3.2    United States
        11.3.3    EU-4 and the United Kingdom
            11.3.3.1    Germany
            11.3.3.2    France
            11.3.3.3    Italy
            11.3.3.4    Spain
            11.3.3.5    United Kingdom
        11.3.4    Japan
        11.3.5    India 
12    United States Warm Autoimmune Hemolytic Anemia Market (2017-2032)
    12.1    United States Warm Autoimmune Hemolytic Anemia Market Historical Value (2017-2023) 
    12.2    United States Warm Autoimmune Hemolytic Anemia Market Forecast Value (2024-2032)
    12.3    United States Warm Autoimmune Hemolytic Anemia Market (2017-2032) by Drug Class
        12.3.1    Market Overview
        12.3.2    Fostamatinib
        12.3.3    Sutimlimab
        12.3.4    Parsaclisib
        12.3.5    Rilzabrutinib
        12.3.6    Isatuximab  
13    EU-4 and United Kingdom Warm Autoimmune Hemolytic Anemia Market (2017-2032)
    13.1    EU-4 and United Kingdom Warm Autoimmune Hemolytic Anemia Market Historical Value (2017-2023) 
    13.2    EU-4 and United Kingdom Warm Autoimmune Hemolytic Anemia Market Forecast Value (2024-2032)
    13.3    EU-4 and United Kingdom Warm Autoimmune Hemolytic Anemia Market Overview
    13.4    EU-4 and United Kingdom Warm Autoimmune Hemolytic Anemia Market (2017-2032) by Drug Class
        13.4.1    Market Overview
        13.4.2    Fostamatinib
        13.4.3    Sutimlimab
        13.4.4    Parsaclisib
        13.4.5    Rilzabrutinib
        13.4.6    Isatuximab  
14    Japan Warm Autoimmune Hemolytic Anemia Market
    14.1    Japan Warm Autoimmune Hemolytic Anemia Market Historical Value (2017-2023) 
    14.2    Japan Warm Autoimmune Hemolytic Anemia Market Forecast Value (2024-2032)
    14.3    Japan Warm Autoimmune Hemolytic Anemia Market (2017-2032) by Drug Class
        14.3.1    Market Overview
        14.3.2    Fostamatinib
        14.3.3    Sutimlimab
        14.3.4    Parsaclisib
        14.3.5    Rilzabrutinib
        14.3.6    Isatuximab  
15    India Warm Autoimmune Hemolytic Anemia Market
    15.1    India Warm Autoimmune Hemolytic Anemia Market (2017-2032) Historical Value (2017-2023) 
    15.2    India Warm Autoimmune Hemolytic Anemia Market (2017-2032) Forecast Value (2024-2032)
    15.3    India Warm Autoimmune Hemolytic Anemia Market (2017-2032) by Drug Class
        15.3.1    Market Overview
        15.3.2    Fostamatinib
        15.3.3    Sutimlimab
        15.3.4    Parsaclisib
        15.3.5    Rilzabrutinib
        15.3.6    Isatuximab  
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    Japan PMDA
        16.1.4    Others
17    Patent  Analysis
    17.1    Analysis by Type of Patent
    17.2    Analysis by Publication Year
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Patent Age
    17.5    Analysis by CPC Analysis
    17.6    Analysis by Patent Valuation 
    17.7    Analysis by Key Players
18    Grants  Analysis
    18.1    Analysis by Year
    18.2    Analysis by Amount Awarded
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Grant Application
    18.5    Analysis by Funding Institute
    18.6    Analysis by NIH Departments
    18.7    Analysis by Recipient Organization 
19    Clinical Trials Analysis
    19.1     Analysis by Trial Registration Year
    19.2    Analysis by Trial Status
    19.3    Analysis by Trial Phase
    19.4    Analysis by Therapeutic Area
    19.5    Analysis by Geography
20    Funding and Investment Analysis
    20.1    Analysis by Funding Instances
    20.2    Analysis by Type of Funding
    20.3    Analysis by Funding Amount
    20.4    Analysis by Leading Players
    20.5    Analysis by Leading Investors
    20.6    Analysis by Geography
21    Partnership and Collaborations Analysis
    21.1    Analysis by Partnership Instances
    21.2    Analysis by Type of Partnership
    21.3    Analysis by Leading Players
    21.4    Analysis by Geography
22    Supplier Landscape
    22.1    Rigel Pharmaceuticals 
        22.1.1    Financial Analysis
        22.1.2    Product Portfolio
        22.1.3    Demographic Reach and Achievements
        22.1.4    Mergers and Acquisitions
        22.1.5    Certifications
    22.2    Apellis Pharmaceuticals, Inc. 
        22.2.1    Financial Analysis
        22.2.2    Product Portfolio
        22.2.3    Demographic Reach and Achievements
        22.2.4    Mergers and Acquisitions
        22.2.5    Certifications
    22.3    Johnson & Johnson 
        22.3.1    Financial Analysis
        22.3.2    Product Portfolio
        22.3.3    Demographic Reach and Achievements
        22.3.4    Mergers and Acquisitions
        22.3.5    Certifications
    22.4    Sanofi
        22.4.1    Financial Analysis
        22.4.2    Product Portfolio
        22.4.3    Demographic Reach and Achievements
        22.4.4    Mergers and Acquisitions
        22.4.5    Certifications
    22.5    Incyte Corporation 
        22.5.1    Financial Analysis
        22.5.2    Product Portfolio
        22.5.3    Demographic Reach and Achievements
        22.5.4    Mergers and Acquisitions
        22.5.5    Certifications
    22.6    Momenta Pharmaceuticals 
        22.6.1    Financial Analysis
        22.6.2    Product Portfolio
        22.6.3    Demographic Reach and Achievements
        22.6.4    Mergers and Acquisitions
        22.6.5    Certifications
    22.7    Teva Pharmaceuticals Ltd. 
        22.7.1    Financial Analysis
        22.7.2    Product Portfolio
        22.7.3    Demographic Reach and Achievements
        22.7.4    Mergers and Acquisitions
        22.7.5    Certifications
    22.8    F. Hoffmann La Roche Ltd. 
        22.8.1    Financial Analysis
        22.8.2    Product Portfolio
        22.8.3    Demographic Reach and Achievements
        22.8.4    Mergers and Acquisitions
        22.8.5    Certifications
    22.9    Alexion Pharmaceuticals Inc. 
        22.9.1    Financial Analysis
        22.9.2    Product Portfolio
        22.9.3    Demographic Reach and Achievements
        22.9.4    Mergers and Acquisitions
        22.9.5    Certifications
    22.10    Immunovant 
        22.10.1    Financial Analysis
        22.10.2    Product Portfolio
        22.10.3    Demographic Reach and Achievements
        22.10.4    Mergers and Acquisitions
        22.10.5    Certifications
23    Warm  Autoimmune Hemolytic Anemia Treatment Drugs - Distribution Model (Additional Insight)
    23.1    Overview 
    23.2    Potential Distributors 
    23.3    Key Parameters for Distribution Partner Assessment 
24    Key Opinion Leaders (KOL) Insights (Additional Insight)
25    Company Competitiveness Analysis (Additional Insight)

    25.1    Very Small Companies
    25.2    Small Companies
    25.3    Mid-Sized Companies
    25.4    Large Companies
    25.5    Very Large Companies
26    Payment Methods (Additional Insight)
    26.1    Government Funded
    26.2    Private Insurance
    26.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

 

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Key Questions Answered in the Report

The market is anticipated to grow at a CAGR of 15.9% during the forecast period of 2024-2032, driven by the heightened awareness surrounding autoimmune diseases across the 8 major markets.

The market demand is driven by increased healthcare expenditure and improved access to healthcare products and services.

One of the significant trends in the market is increasing research initiatives to develop and commercialize safer and more effective treatment therapies to manage the condition. In November 2023, Phase 3 FORWARD trial results of Fostamatinib showed promising results for warm autoimmune hemolytic anemia patients. 

Based on the drug class, the market is segmented into Fostamatinib, Sutimlimab, Parsaclisib, Rilzabrutinib, and Isatuximab.

Distribution channels in the market include hospital pharmacies, online pharmacies, and retail pharmacies.

The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. 

Key players involved in the market are Rigel Pharmaceuticals, Apellis Pharmaceuticals, Inc., Johnson & Johnson, Sanofi, Incyte Corporation, Momenta Pharmaceuticals, Teva Pharmaceuticals Ltd., F. Hoffmann La Roche Ltd., Alexion Pharmaceuticals Inc., and Immunovant.

Purchase Full Report

Mini Report

$ 3299     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 6599     $5999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8799     $7999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 9899     $8999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER